Venglustat,Sanofi,"Substrate 
Reduction",FAILED,"Worsened 
symptoms; 
depleted 
essential lipids."
BIA 28-6156,Bial,"Allosteric 
Activator",Phase 2,"Activates but 
may not 
rescue from ER 
as effectively."
PR001,Prevail/Lilly,"Gene Therapy 
(AAV9)",Phase 1/2,"Invasive 
delivery; high 
cost; safety 
risks."
Ambroxol,Generic,"Competitive 
Chaperone",Phase 3,"Requires 
massive doses; 
active site 
inhibition risk."
